Aerovate Therapeutics Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019
Period Ending	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020	Dec '19 Dec 31, 2019
Revenue	0.18	-	-	-	-
Cost of Revenue	0.19	-	-	-	-
Gross Profit	-0.02	-	-	-	-
Selling, General & Admin	8.29	10.91	17.1	4.4	4.06
Research & Development	8.32	9.89	10.47	6.88	7.36
Operating Expenses	16.62	20.81	27.57	11.27	11.42
Operating Income	-16.63	-20.81	-27.57	-11.27	-11.42
Interest Expense	-0.04	-0.07	-0.57	-	-
Currency Exchange Gain (Loss)	-	-	-	0.06	-0.06
Other Non Operating Income (Expenses)	-18.02	0.97	-5.95	-0.03	-0.02
Pretax Income	-34.69	-19.9	-34.08	-11.24	-11.5
Income Tax Expense	-1.04	0.78	0.43	-	-
Net Income	-33.66	-20.68	-34.51	-11.24	-11.5
Net Income to Common	-33.66	-20.68	-34.51	-11.24	-11.5
Shares Outstanding (Basic)	18	17	17	17	14
Shares Outstanding (Diluted)	18	17	17	17	14
Shares Change (YoY)	6.01%	0.35%	2.40%	16.29%	-
EPS (Basic)	-1.86	-1.21	-2.03	-0.68	-0.81
EPS (Diluted)	-1.86	-1.21	-2.03	-0.68	-0.81
Free Cash Flow	-14.99	-13.72	-14.59	-11.09	-10.15
Free Cash Flow Per Share	-0.83	-0.81	-0.86	-0.67	-0.71
Gross Margin	-8.52%	-	-	-	-
Operating Margin	-9450.57%	-	-	-	-
Profit Margin	-19122.16%	-	-	-	-
Free Cash Flow Margin	-8519.32%	-	-	-	-
EBITDA	-16.43	-20.31	-27.35	-11.07	-11.24
D&A For EBITDA	0.21	0.5	0.21	0.2	0.18
EBIT	-16.63	-20.81	-27.57	-11.27	-11.42
Advertising Expenses	-	-	-	0.26	0.11

Updated Mar 4, 2024. Source: S&P Global Market Intelligence. Standard template. Financial Sources.